Indivior announced a proposed private offering of USD 400 million of convertible senior notes due 2031, with an option for initial purchasers to buy up to an additional USD 60 million. If fully exercised, the total issuance would be USD 460 million. Indivior said it plans to use about USD 239 million of net proceeds plus about USD 102 million of cash on hand to repay borrowings and terminate its term loan and revolving credit facility agreement. The company also expects to use up to about USD 75 million of net proceeds to repurchase common shares from certain note purchasers in concurrent private transactions.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Indivior Pharmaceuticals Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202603120700PRIMZONEFULLFEED1001169751) on March 12, 2026, and is solely responsible for the information contained therein.
Comments